Dr Simon Feys discusses his award-winning research on viral-associated pulmonary aspergillosis (VAPA) in critically ill patients, highlighting key insights into its pathophysiology, diagnostic challenges, and treatment gaps. His work combines clinical expertise with multi-omics analysis to improve understanding, detection, and management of this often-overlooked but potentially deadly fungal superinfection.

Dr. Jon Salmanton-García discusses unmet needs in preventing and treating respiratory infections in haematology patients, highlighting real-world data insights and the urgent need for targeted vaccines and antivirals.

Respiratory syncytial virus (RSV) is often of increased concern in the autumn and winter months, especially for women who are pregnant, or those with newborns.1 Worldwide, RSV is the second leading cause of death (second to malaria) in children during ...

HIV vaccine development harnesses breakthroughs in structure-based antigen design, sequencing, and single-cell analysis to create potent vaccines. Prof. Barney Graham, Professor of Medicine, Microbiology, Chemistry and Immunology, Morehouse School of Medicine in Atlanta, Georgia, USA explores advances reported at CROI 2024, emphasizing advances in targeting antibody lineages and augmenting CD8+ T cell responses, and highlighting sustaining funding models for HIV research and it's imperativeness for addressing broader public health issues.

HIV vaccine development, emphasizing HIV, RSV, and coronavirus COVID-19 research is discussed by Prof. Barney Graham. This information is crucial for immunologists, virologists, and those in vaccine research. Learn from cross-disciplinary strategies. You, as healthcare professionals in these fields, need to grasp these insights for innovation. HIV, RSV, and coronavirus studies offer valuable lessons. Keep up with the latest in vaccine technology.

Learn about the integration of the latest data in antiretroviral management of HIV, challenges clinicians may face when adopting new strategies and updates from the Conference of Retroviruses and Opportunistic Infections (CROI) 2024 are reported here by Dr Eric Daar, Division of HIV Medicine, Harbor-UCLA Medical Center, Atlanta, GA, USA.

Initial attempts to develop a HIV vaccine focused on creating a vaccine that would generate neutralizing antibodies against the virus, using portions of the HIV envelope from prototype laboratory isolates. The initial attempts using monomeric envelope proteins of largely laboratory ...

Molnupiravir is an oral antiviral medication that has shown to be effective in treating COVID-19. Nirmatrelvir/ritonavir is a combination of two drugs that have been granted emergency use authorization for the treatment of COVID-19. Dr Jon Salmanton-Garcia (University of ...

The MONET phase 3 study investigated the safety and efficacy of several monoclonal antibodies (sotrovimab tixagevimab/cilgavimab, and nirmatrelvir–ritonavir) for the treatment of COVID-19 in non-hospitalised adult patients. We caught up with Dr. Valentina Mazzotta (IRCCS, Rome, Italy) to discuss ...